💊 5 fármacos clave contra el cáncer de mama en China

Terapias ADC e inhibidores PARP están marcando tendencia en HER2+ y BRCA.

🎥 Descubre más en el video

#CáncerDeMama #HER2 #BRCA #Oncología #ADC #PARP #ChinaPharma

🚀 Cambio clave en cáncer de mama HER2+

Nuevo ADC anti-HER2 de Hengrui muestra resultados sólidos en pacientes avanzados 👀

Competencia con trastuzumab deruxtecan se intensifica.

👉 ¿Qué hace únicos estos datos?

#HER2 #CancerDeMama #ADC #Oncologia #Biotech #Hengrui #SHRA1811 #DengYueMed

HER2 testing is transforming care for HER2-altered tumors. 💥Join Geoffrey Ku, MD, and colleagues at USCAP 2026 to explore testing across GI & lung cancers and its impact on treatment decisions.

Attend in person or virtually. 👉 https://bit.ly/46RwBQL

#Oncology #HER2

🔜 #ELCC26 @myesmo.bsky.social
🔥Don’t miss the target: BRAF, HER2, METex14 and EGFR exon20 in focus
☑️ #BRAF #HER2 #METex14 #EGFRex20ins
🎙️Chair: Dr. Caicun Zhou, Dr. Natasha Leighl
@oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social
🔥Predictive immunohistochemistry for ADCs
☑️ #HER2 #MET #DigitalPathology #AI
🎙️Chair: Dr. Fernando Lopez-Rios, Dr. Umberto Malapelle
@oncoalert.bsky.social LARVOL #LCSM

Synapse: Your Connection to our MSK Authors
Meet: Elisa De Stanchina
Research Focus: Res Facilities; Lab Member

Trastuzumab deruxtecan resistance via loss of HER2 expression and binding
synapse.mskcc.org/synapse/work...

#TrastuzumabDeruxtecan #HER2
#BreastCancerResearch #TargetedTherapy #Oncology

Call for Papers: This Special Collection examines clinical and translational developments in high‑risk HER2+ early breast cancer, including response‑adapted strategies, ADCs, and biomarker‑guided approaches. buff.ly/3jv7zmw #BreastCancer #Oncology #HER2 #MedOnc #ClinicalTrials

Nuestro póster destaca cuatro clases terapéuticas clave en oncología:
🔬 #ADC (conjugados anticuerpo-fármaco)
🎯 Terapias dirigidas a #HER2
🧬 Inhibidores de #CDK4/6
💊 Inhibidores de #PARP

#CancerDeMama #Oncología #InnovacionFarmaceutica #Farmaceutica #SaludGlobal #DengYueMedicinasEnHongKong

Dr Dennis Slamon's journey as the pioneer of Herceptin, inspires a movie of his life, "Living Proof."

Dr. Dennis Slamon's Inspiration Behind "Living Proof" | Stand Up To Cancer

youtube.com/watch?v=vsa7...

YouTube, Stand Up To Cancer

#Herceptin #HER2

📊 En este póster compartimos 5 empresas biofarmacéuticas chinas líderes en innovación contra el cáncer de mama y algunas de sus terapias clave.
💬 ¿Conocías alguna de estas compañías?

#CáncerDeMama #ADC #HER2 #InhibidoresCDK46 #InnovaciónEnSalud #DengYueMedicinasEnHongKong

China impulsa la innovación en oncología.
📊 Descubre en este póster 5 medicamentos innovadores para el cáncer de mama.

#CáncerDeMama #Dalpiciclib #Pyrotinib #Chidamide #Envafolimab #DisitamabVedotin #HER2 #HER2Positive #TargetedTherapy #ADC #TerapiasInnovadoras #DengYueMedicinasEnHongKong

Ther Adv Med Oncol: Real‑world pyrotinib beyond progression vs rechallenge in HER2+ mBC (incl. brain mets): PFS2 ~7.2 vs 6.3 mo (NS); OS 31.6 vs 21.0 mo (trend). CNS subgroup also benefited. Read: 【🔗https://buff.ly/xsK4lFw 】 #BreastCancer #HER2 #BrainMets #Oncology

💊FDA Approval Update | #HERNEXEOS® (#zongertinib tablets): the first targeted therapy for #HER2 mutant advanced #NSCLC
🔹For adults as an initial treatment option
🔹11% of patients with a complete response
🔹65% of patients with a partial response

Zongertinib Approved by FDA for HER2+ NSCLC Zongertinib receives FDA accelerated approval for advanced HER2-mutant NSCLC, expanding targeted treatment options.

Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #NSCLC #MedEd #MedOnc #MedNews #LungCancer #HER2 #TargetedTherapy #FDAApproval

Analysis of 346 BCBM cases from the GEICAM RegistEM registry reveals faster CNS progression and poorer survival in TNBC and HER2+ subtypes, with major differences between de novo vs subsequent brain metastases.
🔗 buff.ly/74yHwuH
#BreastCancer #BrainMets #HER2 #TNBC #RealWorldEvidence

Lung Cancer Targeted Therapies OncTalk 2026 {{MetaTags.description}}

Register:
give.cancergrace.org/event/lung-c...

Support free patient education 💙 #LungCancer #EGFR #HER2

Diagnostic value of peripheral blood inflammatory indices for breast cancer grade and immunohistochemical markers: a retrospective observational study - BMC Cancer Introduction Breast cancer remains a leading global health burden with rising incidence, particularly in low- and middle-income countries. Emerging evidence suggests that systemic inflammatory indices...

Neutrophil-to-lymphocyte ratio (NLR) shows moderate value in predicting #BreastCancer grade and #HER2 status — a simple, low-cost blood marker with potential for early risk stratification.
#Oncology #Biomarkers #NLR link.springer.com/article/10.1...

Synapse: Your Connection to our MSK Authors
Meet: Sohrab Prakash Shah
Research Focus: BIOSTAT/EPIDEMIOLOGY; Chief Attending

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
synapse.mskcc.org/synapse/work...

#UrothelialCancer #BladderCancer #HER2

Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity Statement of Significance: A HER2-targeting eribulin-containing ADC had exhibited good plasma stability; BB-1701 had potent antitumor activities against mu

Antibody Therapeutics(IF=4.5, Oxford University Press)
📢📢Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity
academic.oup.com/abt/article/...
#ADC #HER2 #Antibody

ctDNA findings from the Ni‑High phase Ib trial: ERBB2 focal amplification and early mMAF decline strongly predict improved outcomes with trastuzumab + nivolumab + chemo in HER2+ aGC.
🔗https://buff.ly/S2kBuFe
#GastricCancer #HER2 #ctDNA

第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく
ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04

stellanews.life/technology/8...

#GastricCancer #HER2 #ENHERTU #AntibodyDrugConjugate #DESTINYGastric04

【第一三共、HER2陽性胃がん二次治療で中国承認】

✔ トラスツズマブ前治療後のHER2陽性進行・再発胃がんで承認
✔ 第3相DESTINY-Gastric04に基づく判断
✔ 画期的治療薬指定・優先審査の下で取得

トラスツズマブ デルクステカン（商品名エンハーツ）は抗HER2抗体薬物複合体。中国では三次治療で条件付き承認済みで、今回は二次治療に拡大。生存期間など詳細指標は本発表では限定的であり、追加データの確認が必要。
#胃がん #HER2 #抗体薬物複合体

When first-line cancer treatment stops working, knowing your options and speaking up matters. This man shares his experience with second-line HER2 therapy, biopsy decisions, and why self-advocacy can shape your care journey. #CancerCare #SelfAdvocacy #HER2 #PatientEmpowerment #Oncology

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compare....

#Article in @MedComm_MC
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...

#ClinicalTrial

Zanidatamab (Baihe’an®): Un avance clave en el cáncer de vías biliares HER2 positivo

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Zanidatamab #BaiheAn #HER2 #BiliaryTractCancer #Oncology #BispecificAntibody #TargetedTherapy #BreakthroughTherapy #CSCO #CDE #FDA

#brca #hereditarycancer #genetics #patientexperience
#EarlyDetection #her2 #prostatecancer #breastcancer #cysticfibrosis #sicklecell #heartdisease #diabetes #pancreaticcancer

Bridgy Fed Bridgy Fed is a bridge between decentralized social networks like the fediverse, Bluesky, and web sites and blogs.

fed.brid.gy/bsky/globalv...

#HER2 #NEU
headlines-world.com/advanced-sea...
ПЛАЖА ЈУТА
multi-search-tag-explorer.headlines-world.com/advanced-sea...
#MIROSLAV #BENKA
multi-search-tag-explorer.headlines-world.com/advanced-sea...
aepiot.com

La #FDA a accordé la désignation de "thérapie révolutionnaire" au #Sévabertinib pour le traitement de 1ère intention des patients atteints de #CancerDuPoumon non à petites cellules non réséquable ou métastatique présentant des mutations activatrices #HER2
www.targetedonc.com/view/fda-gra...

Join Rachna Shroff, MD, MS, FASCO at an ASCO GI 2026 satellite symposium exploring HER2-positive GI cancers, from molecular testing to targeted therapy across gastric/GEJ, CRC, and biliary tract cancers.

👉 Register: https://bit.ly/48FksQl

#ASCOGI2026 #HER2 #GICancers

The role of HER2 in advanced bladder cancer is rapidly expanding.

📖 Read the full clinical thought commentary for expert perspectives on testing strategies, treatment sequencing, and future directions in HER2-positive urothelial carcinoma: https://bit.ly/4pIHX11

#HER2 #BladderCancer